Combinatorial cancer immunotherapy
AssigneeSenti Biosciences, Inc.
InventorsTimothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
Claims29
A method of reducing tumor volume in a subject, the method comprising delivering to a subject having a tumor a composition comprising mesenchymal stem cells engineered to produce multiple effector molecules that modulate tumor-mediated immunosuppressive mechanisms, in an effective amount to reduce the volume of the tumor.
(canceled)
(canceled)
(canceled)
(canceled)
16-19. (canceled)
A mesenchymal stem cell engineered to produce multiple effector molecules that modulate tumor-mediated immunosuppressive mechanisms, wherein each of the effector molecules is selected from the group consisting of:
- MIP1a (CCL3), MIP1b (CCL5), CCL21, CXCL9, CXCL10 CXCL11, IFN-γ, IL-12, IL-2, IL-4, IL-15, IL-16, IL-7, IL-9, IL-36γ, IL-18, IL-21, IL-1β, OX40-ligand, CD40L, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, CCR9, CXCR3, CXCR4, CCR2, CCR4, FPR2, VEGFR, IL6R, CXCR1, CSCR7, and PDGFR.
A composition comprising mesenchymal stem cells engineered to produce multiple effector molecules that modulate tumor-mediated immunosuppressive mechanisms formulated in an effective amount to reduce the volume of a tumor in a subject wherein each of the effector molecules is selected from the group consisting of:
- MIP1a (CCL3), MIP1b (CCL5), CCL21, CXCL9, CXCL10 CXCL11, IFN-β, IFN-γ, IL-12, IL-2, IL-4, IL-15, IL-16, IL-7, IL-9, IL-36γ, IL-18, IL-21, IL-1β, OX40-ligand, CD40L, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, CCR9, CXCR3, CXCR4, CCR2, CCR4, FPR2, VEGFR, IL6R, CXCR1, CSCR7, and PDGFR.
(canceled)
(canceled)
26-28. (canceled)
33-39. (canceled)
Dependencies are inferred from the claim text.